JP2019519572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519572A5 JP2019519572A5 JP2018568253A JP2018568253A JP2019519572A5 JP 2019519572 A5 JP2019519572 A5 JP 2019519572A5 JP 2018568253 A JP2018568253 A JP 2018568253A JP 2018568253 A JP2018568253 A JP 2018568253A JP 2019519572 A5 JP2019519572 A5 JP 2019519572A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxyacetoxy
- cyclopentyl
- phenyl
- methylpyrrolidinium
- carboxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 24
- -1 ester compound Chemical class 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 230000000414 obstructive effect Effects 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims 6
- 230000003454 betamimetic effect Effects 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 6
- 229960003744 loteprednol etabonate Drugs 0.000 claims 6
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 231100000252 nontoxic Toxicity 0.000 claims 5
- 230000003000 nontoxic effect Effects 0.000 claims 5
- KTCKPDPJTAUEPP-UHFFFAOYSA-N 2-[3-(2-cyclopentyl-2-hydroxy-2-phenylacetyl)oxy-1-methylpyrrolidin-1-ium-1-yl]acetate Chemical compound C1[N+](C)(CC([O-])=O)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 KTCKPDPJTAUEPP-UHFFFAOYSA-N 0.000 claims 4
- KTCKPDPJTAUEPP-SGDIKTSBSA-N 2-[3-[(2R)-2-cyclopentyl-2-hydroxy-2-phenylacetyl]oxy-1-methylpyrrolidin-1-ium-1-yl]acetate Chemical compound C1[N+](C)(CC([O-])=O)CCC1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 KTCKPDPJTAUEPP-SGDIKTSBSA-N 0.000 claims 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 4
- FIAFMTCUJCWADZ-NRQRHMLOSA-M [1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OCC)(C)CCC1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 FIAFMTCUJCWADZ-NRQRHMLOSA-M 0.000 claims 4
- FIAFMTCUJCWADZ-UHFFFAOYSA-M [1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OCC)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 FIAFMTCUJCWADZ-UHFFFAOYSA-M 0.000 claims 4
- BYLYKBTVPVGVIU-MZXPGCLASA-M [1-(2-methoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OC)(C)CCC1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 BYLYKBTVPVGVIU-MZXPGCLASA-M 0.000 claims 4
- BYLYKBTVPVGVIU-UHFFFAOYSA-M [1-(2-methoxy-2-oxoethyl)-1-methylpyrrolidin-1-ium-3-yl] 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OC)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 BYLYKBTVPVGVIU-UHFFFAOYSA-M 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 239000000043 antiallergic agent Substances 0.000 claims 4
- 230000000241 respiratory effect Effects 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- 230000009885 systemic effect Effects 0.000 claims 3
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 2
- CCJFMGVZQISCHN-IQQGIHLUSA-M [1-methyl-1-(2-octoxy-2-oxoethyl)pyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C1[N+](CC(=O)OCCCCCCCC)(C)CCC1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 CCJFMGVZQISCHN-IQQGIHLUSA-M 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- 239000003623 enhancer Substances 0.000 claims 2
- 229950006990 etiprednol dicloacetate Drugs 0.000 claims 2
- QAIOVDNCIZSSSF-RFAJLIJZSA-N etiprednol dicloacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](OC(=O)C(Cl)Cl)(C(=O)OCC)[C@@]1(C)C[C@@H]2O QAIOVDNCIZSSSF-RFAJLIJZSA-N 0.000 claims 2
- 229960001022 fenoterol Drugs 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229940015042 glycopyrrolate Drugs 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 229960001664 mometasone Drugs 0.000 claims 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 2
- 229960004017 salmeterol Drugs 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357711P | 2016-07-01 | 2016-07-01 | |
| US201662357730P | 2016-07-01 | 2016-07-01 | |
| US62/357,711 | 2016-07-01 | ||
| US62/357,730 | 2016-07-01 | ||
| PCT/US2017/040348 WO2018006001A1 (en) | 2016-07-01 | 2017-06-30 | Compositions and methods for treatment of copd |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019519572A JP2019519572A (ja) | 2019-07-11 |
| JP2019519572A5 true JP2019519572A5 (enExample) | 2020-08-06 |
Family
ID=60787597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568253A Pending JP2019519572A (ja) | 2016-07-01 | 2017-06-30 | Ｃｏｐｄを処置するための組成物および方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190224164A1 (enExample) |
| EP (1) | EP3478365A4 (enExample) |
| JP (1) | JP2019519572A (enExample) |
| CA (1) | CA3029621A1 (enExample) |
| WO (1) | WO2018006001A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021528107A (ja) * | 2018-07-31 | 2021-10-21 | コリア・インスティトゥート・オブ・オリエンタル・メディスン | 羅漢果抽出物を有効成分として含有する呼吸器疾患の予防、改善、または治療用組成物 |
| WO2021207729A1 (en) * | 2020-04-10 | 2021-10-14 | Mubarak Kamal Khan | Compositions and methods for modulating ace2 receptor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1948596B1 (en) * | 2005-11-10 | 2011-10-19 | Nicholas S. Bodor | Soft anticholinergic esters |
| US7417147B2 (en) * | 2005-11-10 | 2008-08-26 | Bodor Nicholas S | Soft anticholinergic zwitterions |
| DK2968267T3 (en) * | 2013-03-15 | 2018-06-25 | Bodor Laboratories Inc | SOFT ANTICHOLINERGE ESTERS FOR TREATMENT OF HYPERHIDROSE |
| WO2015138700A1 (en) * | 2014-03-13 | 2015-09-17 | Bodor Laboratories, Inc. | Use of selected anticholinergic zwitterions |
-
2017
- 2017-06-30 CA CA3029621A patent/CA3029621A1/en not_active Abandoned
- 2017-06-30 EP EP17821380.7A patent/EP3478365A4/en not_active Withdrawn
- 2017-06-30 JP JP2018568253A patent/JP2019519572A/ja active Pending
- 2017-06-30 WO PCT/US2017/040348 patent/WO2018006001A1/en not_active Ceased
- 2017-06-30 US US16/312,995 patent/US20190224164A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2309503T3 (es) | Medicamento que comprende un agonista beta 2 de larga duracion, muy potente, en combinacion con otros ingredientes activos. | |
| RU2019100425A (ru) | Новая доза и препаративная форма | |
| JP2007520508A5 (enExample) | ||
| RU2018115685A (ru) | Фармацевтическая композиция | |
| JP2018199684A5 (enExample) | ||
| JP2013531056A5 (enExample) | ||
| CA2496699A1 (en) | Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids | |
| JP2004500433A (ja) | チオトロピウムとブデソニドを含む組合せ医薬 | |
| RU2006132038A (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| JP2004514739A5 (enExample) | ||
| JP2013542940A5 (enExample) | ||
| EA023839B1 (ru) | Комбинации антагониста мускариновых рецепторов и агониста бета-2-адренорецепторов | |
| EP2400950A1 (en) | Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol | |
| JP2004500429A (ja) | チオトロピウム及びロフレポニドを含む医薬用の組み合わせ | |
| JP2004500430A (ja) | ホルモテロール及びブデソニドを含有する医薬用の組み合わせ | |
| JP2009502997A (ja) | 噴霧投与用の長時間作用型ベータ２−アゴニストを含む医薬製剤 | |
| JP2015519356A5 (enExample) | ||
| JP2004500435A (ja) | チオトロピウムとモメタゾンを含む組合せ医薬 | |
| JP2020023536A (ja) | Ｃｏｐｄの治療のためのフォルモテロール及びブデソニドの組み合わせ | |
| EP2934479A1 (en) | Ciclesonide for the treatment of airway disease in horses | |
| JP2007505829A5 (enExample) | ||
| JP2019519572A5 (enExample) | ||
| JP2018058881A (ja) | 医薬組成物 | |
| JP2011500731A5 (enExample) | ||
| HRP20140818T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata |